The commercial engine behind your scientific breakthroughs
Propel Biosciences is the Commercialization Acceleration Partner
We help scientific and technical innovators transform breakthrough potential into market momentum. We bring together strategic clarity, targeted execution, and leadership support so you can grow confidently in competitive, complex markets.
Our approach
Where scientific potential becomes commercial success.
Propel closes the gap between innovation and adoption using:
- The Propel Commercial Acceleration Playbook™: a proven framework customized for every client
- Precision targeting supported by proprietary data
- Targeted outreach and early pipeline creation
- Messaging and commercial narrative refinement
- Partnership and alliance development
- Sales enablement and execution support
- Fractional commercial leadership
We do more than advise. We help you accelerate.
Meet the Founder & CEO
Susan Nichols
Susan Nichols brings more than 25 years of commercial leadership across diagnostics, cell and gene therapy, and drug development, including more than 15 years in cell and gene therapy. She began in diagnostics at Roche, Abbott, and Thermo Fisher, then led commercial and partnering work across CGT tools, CDMOs, and drug developers, including Invetech, ViroCell Biologics as Chief Business Officer, and Falcon Therapeutics as CEO. Across her career she has built commercial pipelines exceeding $1B. Today she also serves as Fractional Chief Commercial Officer at SCTbio, an EU-GMP cell and gene therapy CDMO. Susan writes the Escaping Commercial Gravity newsletter for CGT founders and commercial leaders, shared with a LinkedIn community of more than 22,000. She founded Propel to give breakthrough science the commercialization systems it deserves.
Propel brings together a collective of senior business development and sales consultants who have led commercialization across biotech and life science organizations.